Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Can J Gastroenterol Hepatol. 2017; 2017:7365937.
View in:
PubMed
subject areas
Adult
Adult
Biological Therapy
Biological Therapy
Emergency Service, Hospital
Emergency Service, Hospital
Female
Female
Gastrointestinal Agents
Gastrointestinal Agents
Hospitalization
Hospitalization
Humans
Humans
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases
Insurance, Pharmaceutical Services
Insurance, Pharmaceutical Services
Male
Male
Middle Aged
Middle Aged
Ontario
Ontario
Proportional Hazards Models
Proportional Hazards Models
Retrospective Studies
Retrospective Studies
Treatment Outcome
Treatment Outcome
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor-alpha
authors with profiles
Amir Rumman